These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 10834270

  • 1. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
    Lee HH, Wilson WR, Denny WA.
    Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
    [Abstract] [Full Text] [Related]

  • 2. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
    Lee HH, Wilson WR, Ferry DM, van Zijl P, Pullen SM, Denny WA.
    J Med Chem; 1996 Jun 21; 39(13):2508-17. PubMed ID: 8691448
    [Abstract] [Full Text] [Related]

  • 3. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
    Palmer BD, Wilson WR, Anderson RF, Boyd M, Denny WA.
    J Med Chem; 1996 Jun 21; 39(13):2518-28. PubMed ID: 8691449
    [Abstract] [Full Text] [Related]

  • 4. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
    Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA.
    J Med Chem; 2003 Jan 02; 46(1):169-82. PubMed ID: 12502371
    [Abstract] [Full Text] [Related]

  • 5. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism.
    Siim BG, Hicks KO, Pullen SM, van Zijl PL, Denny WA, Wilson WR.
    Biochem Pharmacol; 2000 Oct 01; 60(7):969-78. PubMed ID: 10974206
    [Abstract] [Full Text] [Related]

  • 6. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine.
    Wilson WR, Siim BG, Denny WA, van Zijl PL, Taylor ML, Chambers DM, Roberts PB.
    Radiat Res; 1992 Sep 01; 131(3):257-65. PubMed ID: 1438685
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
    Henderson ND, Plumb JA, Robins DJ, Workman P.
    Anticancer Drug Des; 1996 Sep 01; 11(6):421-38. PubMed ID: 8836108
    [Abstract] [Full Text] [Related]

  • 8. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J, Oleschuk CJ, Guziec F, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A.
    Cancer Chemother Pharmacol; 2002 Feb 01; 49(2):101-10. PubMed ID: 11862423
    [Abstract] [Full Text] [Related]

  • 9. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.
    Patterson LH, Craven MR, Fisher GR, Teesdale-Spittle P.
    Oncol Res; 1994 Feb 01; 6(10-11):533-8. PubMed ID: 7620222
    [Abstract] [Full Text] [Related]

  • 10. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
    Wilson WR, Denny WA, Pullen SM, Thompson KM, Li AE, Patterson LH, Lee HH.
    Br J Cancer Suppl; 1996 Jul 01; 27():S43-7. PubMed ID: 8763844
    [Abstract] [Full Text] [Related]

  • 11. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.
    Moselen JW, Hay MP, Denny WA, Wilson WR.
    Cancer Res; 1995 Feb 01; 55(3):574-80. PubMed ID: 7834627
    [Abstract] [Full Text] [Related]

  • 12. New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
    Amin KM, Ismail MM, Noaman E, Soliman DH, Ammar YA.
    Bioorg Med Chem; 2006 Oct 15; 14(20):6917-23. PubMed ID: 16843668
    [Abstract] [Full Text] [Related]

  • 13. Novel N-oxide of naphthalimides as prodrug leads against hypoxic solid tumor: synthesis and biological evaluation.
    Yin H, Xu Y, Qian X, Li Y, Liu J.
    Bioorg Med Chem Lett; 2007 Apr 15; 17(8):2166-70. PubMed ID: 17331719
    [Abstract] [Full Text] [Related]

  • 14. Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs.
    Siim BG, Atwell GJ, Anderson RF, Wardman P, Pullen SM, Wilson WR, Denny WA.
    J Med Chem; 1997 Apr 25; 40(9):1381-90. PubMed ID: 9135035
    [Abstract] [Full Text] [Related]

  • 15. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
    Hay MP, Pruijn FB, Gamage SA, Liyanage HD, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA.
    J Med Chem; 2004 Jan 15; 47(2):475-88. PubMed ID: 14711317
    [Abstract] [Full Text] [Related]

  • 16. Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide.
    Wilson WR, Van Zijl P, Denny WA.
    Int J Radiat Oncol Biol Phys; 1992 Jan 15; 22(4):693-6. PubMed ID: 1544839
    [Abstract] [Full Text] [Related]

  • 17. Hypoxia-selective antitumor agents. 4. Relationships between structure, physicochemical properties, and hypoxia-selective cytotoxicity for nitracrine analogues with varying side chains: the "iminoacridan hypothesis".
    Denny WA, Atwell GJ, Anderson RF, Wilson WR.
    J Med Chem; 1990 May 15; 33(5):1288-95. PubMed ID: 2329552
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives.
    Wilson WR, Thompson LH, Anderson RF, Denny WA.
    J Med Chem; 1989 Jan 15; 32(1):31-8. PubMed ID: 2909741
    [Abstract] [Full Text] [Related]

  • 19. Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines.
    Shyam K, Penketh PG, Shapiro M, Belcourt MF, Loomis RH, Rockwell S, Sartorelli AC.
    J Med Chem; 1999 Mar 11; 42(5):941-6. PubMed ID: 10072691
    [Abstract] [Full Text] [Related]

  • 20. Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins.
    Hay MP, Denny WA, Wilson WR.
    Anticancer Drug Des; 1996 Jul 11; 11(5):383-402. PubMed ID: 8765531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.